FEMALE SEXUAL DYSFUNCTION

Female sexual dysfunction may be manifested by decreases in sexual desire, arousal and lubrication, leading to dyspareunia.

OBJECTIVE

Evaluate the response of women with varying degrees of sexual dysfunction to treatment with RegenPRP™.

PROTOCOL

Case series study on 11 women (aged 24-64 years old) presenting symptoms of sexual dysfunction such as hyposexual desire disorder, arousal disorder, orgasmic disorder, and dyspareunia. RegenPRP™ was injected into the anterior vaginal wall, into a space between vagina and urethra most distal from bladder, and into the clitoris. Two standardized sexuality tests, the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS), were used to measure the response to this therapeutic intervention.

RESULTS

Of the 11 patients treated, seven (64%) demonstrated some degree of improvement. The mean FSDS revised score dropped from 17.27 before treatment to 7.27 at 12-16 weeks postinjection. Five of the 7 patients who had a FSDS score over the threshold value of 11 before treatment had a post treatment score below 7. Evaluations based on FSFI score indicated an overall significant improvement after injection.

The scores from the FSFI subscales of desire, arousal, lubrication, and orgasm were all significantly increased after injection of RegenPRP™ (P ≤ 0.05). The changes in the scores for satisfaction and pain were considered not significant (See Table 2).